Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabozantinib Dose Skipping as an Alternative to Dose Reductions

NCT07077161 is registered in ClinicalTrials.gov with dr. Tom van der Hulle as lead sponsor.

NCT NCT07077161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabozantinib Dose Skipping as an Alternative to Dose Reductions
Lead sponsor
dr. Tom van der Hulle
Phase
Phase 2
Overall status
Recruiting
Start date
January 26, 2026
Completion date
September 1, 2028
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma (rcc)